Naoyuki (Jeff) Soga, CEO/owner, Tokiwa Corp., stated: "This new US facility will allow for our continued growth and expansion internationally, while helping us to better meet and serve the needs and expectations of our US and European-based customers, by providing real-time responses, increased speed to market, reduced expenses/costs, and face-to-face dialogue and collaboration. Plus, it will allow us to reach new customers, with our US-made products.”
Tokiwa, which holds over 660 worldwide patents for its unique formulations and componentry, currently owns and operates five cosmetic manufacturing sites in Japan, plus others in China and the Philippines. It maintains sales offices in Tokyo, Paris, New York and Shanghai, to serve the needs of cosmetic companies and brands around the world.
The new facility, located in Monroe Township, New Jersey, encompasses a 153,000-plus square foot standalone building, located on 12-plus acres. The FDA-registered facility will be capable of producing OTC (including UV protection) products and will operate under cGMP certification. Included will be a fully operational R&D laboratory, staffed with both Japanese and locally based formulators and chemists.
The products that will be produced in the US facility will be many of the same items as currently produced in Japan. They will include: mechanical pencils for eyes/lips/brows/face; lipsticks/glosses/stains; powders—loose/pressed/dry/wet/cream; eyeliners—liquid/gel/lead; mascaras, eye shadows, foundations, plus many others. Tokiwa is a full-service provider, currently supplying nearly 90% of their products on a turnkey basis, utilizing both their original formulations and componentry.
Robert Congionti, VP-operations, stated: “Our company's objective is to deliver Japanese quality and standards at competitive prices for all our customers.”
Construction is expected to be completed in Q2, 2019.